BridgeBio
Coverage of BridgeBio in the Nexus archive.
- Sixth Street, KKR Provide BridgeBio $1 Billion Preferred Equity
Sixth Street and KKR have provided BridgeBio with $1 billion in preferred equity. The transaction involves financial support from the two investment firms to BridgeBio.
- Guarding biotech from China and big bets in longevity
STAT's Breakthrough Summit West brought together leaders in healthcare and science to discuss biotech developments. Key topics included BridgeBio's research publication concerns and Retro Biosciences' progress toward clinical trials, with focus on AI's role in drug development.
- STAT+: Hims’ sales miss as telehealth competition grows
Rigel Pharma will market the newly approved breast cancer drug Veppanu, while Roche received European clearance for a new blood test to detect early Alzheimer’s disease. BridgeBio submitted an application to the FDA seeking approval of its drug encaleret to treat patients with autosomal dominant hypocalcemia type 1. Bristol Myers Squibb announced a partnership with Hengrui Pharma covering more than a dozen early-stage programs.